Only the Oncotype DX Breast Recurrence Score^® Test Can Identify Patients Who May, or May Not, Benefit From Chemotherapy.^1-5 EndoPredict^® Cannot.

EndoPredict lacks clinical evidence showing that patients with EPclin* high-risk results may benefit from chemotherapy

Graph Breast Recurrence Score vs EndoPredict

EndoPredict may lead to unnecessary chemotherapy treatment based on its risk classification result

Graph EPclin Low Risk vs High Risk

EndoPredict has not been validated to show prediction of chemotherapy benefit

EndoPredict claims to be chemopredictive, but lacks randomized data within a homogenized cohort

EndoPredict does not stratify patients by nodal status, significantly skewing recurrence risks

Effect of chemotherapy does not vary between EPclin^*and EP molecular score results, suggesting that EndoPredict does not add any additional information beyond clinicopathologic features

Only the Oncotype DX Breast Recurrence Score test result has been proven to predict chemotherapy benefit in both node-negative and node-positive patients.^2,4

See why the Breast Recurrence Score test rises above

*EPclin algorithm: nodal status + tumor size + EP (molecular score).
HER2 = human epidermal growth factor receptor 2; HR = hormone receptor; NSABP B-20 = National Surgical Adjuvant Breast and Bowel Project; TAILORx = Trial Assigning Individualized Options for Treatment.

References

1. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111-121.
2. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734.
3. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111-121.
4. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The Lancet Oncology. 2010;11(1):55-65.
5. Geyer CE, Jr., Tang G, Mamounas EP, et al. 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ Breast Cancer. 2018;4:37.
6. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826.
7. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829-1834.
8. Telli ML, Gradishar WJ, Ward JH. NCCN Guidelines Updates: Breast Cancer. J Natl Compr Canc Netw. 2019;17(5.5):552-555.
9. Andre F, Ismaila N, Henry NL, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO Clinical Practice Guideline Update-integration of results from TAILORx. J Clin Oncol. 2019;37(22):1956-1964.
10. Buus R, Sestak I, Kronenwett R, et al. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst. 2016;108(11).

Icon doctor

Use our online physician portal

Order tests, access results, receive updates, and more in one place.
Sign up now

Treatment Determination

Therapy Selection

Testing And Treating

Understanding Your Diagnosis

Only the Oncotype DX Breast Recurrence Score^® Test Can Identify Patients Who May, or May Not, Benefit From Chemotherapy.^1-5 EndoPredict^® Cannot.

EndoPredict lacks clinical evidence showing that patients with EPclin* high-risk results may benefit from chemotherapy

EndoPredict may lead to unnecessary chemotherapy treatment based on its risk classification result

EndoPredict has not been validated to show prediction of chemotherapy benefit

Use our online physician portal

Quick Links

Only the Oncotype DX Breast Recurrence Score® Test Can Identify Patients Who May, or May Not, Benefit From Chemotherapy.1-5 EndoPredict® Cannot.

EndoPredict lacks clinical evidence showing that patients with EPclin* high-risk results may benefit from chemotherapy

EndoPredict may lead to unnecessary chemotherapy treatment based on its risk classification result

EndoPredict has not been validated to show prediction of chemotherapy benefit

Use our online physician portal

Have questions?

Quick Links

Follow Us

Only the Oncotype DX Breast Recurrence Score^® Test Can Identify Patients Who May, or May Not, Benefit From Chemotherapy.^1-5 EndoPredict^® Cannot.